Remogliflozin etabonate - Avolynt

Drug Profile

Remogliflozin etabonate - Avolynt

Alternative Names: 189075; BHV 091009; GSK 189075; KGT-1681; Remogliflozin

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Avolynt; BHV Pharma; Glenmark Pharmaceuticals Ltd
  • Class Antihyperglycaemics; Glucosides; Hepatoprotectants; Pyrans; Pyrazoles
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis
  • No development reported Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 08 Jan 2018 Glenmark Pharmaceuticals completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in India (PO) (CTRI/2017/10/010043)
  • 08 Jan 2018 Glenmark Pharmaceuticals completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in India (PO) (CTRI/2017/06/008887)
  • 02 Jan 2018 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in India (PO) (CTRI/2017/07/009121)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top